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Increased aldehyde dehydrogenase (ALDH) activity has been found in murine and human hematopoietic stem cells and human multiple myeloma stem cells (MMSCs) . [1] [2] [3] ALDHs are a group of NAD(P)-dependent enzymes involved in drug resistance and retinoic acid metabolism, which are crucial for the protection of stem cells against toxic endogenous and exogenous aldehydes. Recently, the isolation and functional analysis of ALDH1-positive (ALDH1 þ ) cells have been greatly facilitated by the development of the Aldefluor assay. 4 Matsui et al. 3 reported that ALDH1 activity is increased in MMSCs. 5 In the present study, we have addressed the question of whether ALDH1
þ MM cells can initiate MM tumor formation and have evaluated the functional role of ALDH1 in MM cell growth, clonogenic ability and cell signaling.
To determine whether MM cell lines contain an ALDH1 stem cell-like population, we evaluated ALDH1 activity using the Aldefluor assay in 11 human and one mouse MM cell lines. Flow cytometry demonstrated that all MM cell lines contained a very small subset of cells that were positive for ALDH1 (ALDH1 þ ) with a range from 0.1 to 4.85% of total cells (Figures 1a and b) . Human MM cell lines (KMS12BM, XG6, U266 and ARP1) and the mouse MM cell line (5TGM1) had the highest fraction of ALDH1 þ cells with 4.85%, 3.6%, 2.1%, 1.7%, and 1.9%, respectively (Figure 1b) , whereas the remainder of the human MM cell lines (OPM1, JJN3, H929, KMS28, 8226, XG1, OCI-MY5 and OPM2) showed a very low percentage of ALDH1 þ cells (o1.5%; Figure 1b ). We also analyzed ALDH1 þ cells in primary MM samples by combing enzyme activity measurements with flow cytometric determinations of monotypic cytoplasmic immunoglobulin light-chain expression: k in one case and l in another. We found that the k þ tumor contained 0.69% ALDH1 þ /k þ cells (Figure 1c , right panel), whereas the l þ tumor contained only 0.08% ALDH1 þ /l þ cells (not shown). To determine whether ALDH1 þ cells have increased clonogenic potential, the ALDH1 þ fraction was selected from the ARP1 and KMS12BM cell lines. A total of 10 000 ALDH1 þ and ALDH1 -cells per well were seeded in triplicates in a 12-well plate on methylcellulose. 6 After 2 weeks at 37 1C, the number of colonies from ALDH1 þ and ALDH1 -cells was compared. The colonyforming capacity of ALDH1 þ cells in both ARP1 and KMS12BM cells showed greater colony formation capacity than ALDH -cells (5.68% vs 1.15% in APR1 and 2.97% vs 0.83% in KMS12BM, Figure 1d ). Tumorigenicity of ALDH1 þ MM cells was evaluated using an in vivo mouse model. A total of B10 000 ALDH1 þ and 10 000 ALDH1 -cells from ARP1 and KMS12BM cells were injected into the NOD.Cg-Rag1 mice (n ¼ 5 for each group), respectively. After 8 weeks, ARP1-ALDH1 þ and KMS12BM-ALDH1 þ cells showed significantly greater capacity of tumor formation compared with their ALDH1 -cells correspondingly (Figures 1e and f) . To explore ALDH1 þ -related cell signaling, we performed gene expression profiling (GEP) analyses to identify ALDH1-associated transcriptional signatures from three myeloma cell lines. ALDH1 þ cells were selected from XG6, KMS12BM and ARP1 by flow cytometry. GEPs were compared between ALDH1 þ and ALDH1 -cells using a paired Student's t-test. A total of 20 genes identified were significantly differentially expressed between the two fractions, which had a P-value of o0.001 and had greater than twofold change in absolute value. Of those, 17 genes were upregulated and three were downregulated in ALDH1 þ cells. Interestingly, the largest functional category of the ALDH1-associated genes belongs to the chromosomal instability (CIN) genes UBE2C, CDC2, TOP2A, CDCA3, TTK, NEK2, CCNB1, AURKA and AURKB (Figure 2a) . 7 This result is consistent with our recent discovery that a CIN signature was associated with drug resistance and poor prognosis in multiple cancers. 7 In order to determine whether the CIN genes positively correlated with ALDH1 activity are important in MM development, we examined the expression of these 20 genes in purified normal plasma cell (NPC) samples from 22 healthy donors, 44 patients with monoclonal gammopathy of undetermined significance (MGUS), 351 newly diagnosed patients with MM and nine human multiple myeloma cell lines (MMCL). We found that the 17 genes upregulated in ALDH1 þ cells showed significantly increased expression in about 30% of newly diagnosed MM patients compared with NPCs and MGUSs, whereas the three genes downregulated in ALDH1
þ cells decreased their expression in the same 30% of MM patients. Supervised hierarchical clustering clearly showed a subset of MM patients with a similar signature to MM cell lines (Figure 2b ).
Given the strong clinical implication of ALDH1 for acquisition of drug resistance in myeloma, Kaplan-Meier analyses of event-free and overall survivals were used to determine the correlation of ALDH1-associated signature (AAS) with patient outcome. An AAS score (AASS) was developed by the mean ratio of log 2 (upregulated genes)/(downregulated genes) for each sample. After a permutation test of AASS with patient outcome in the Total Therapy 2 trial (TT2), 8 significantly inferior outcomes were observed among the 38 patients with a high level of AASS compared with the remaining 313 patients with a low level of AASS in both event-free and overall survivals in the TT2 trial (Figures 2c and d ; Po0.0001). This positive correlation of high AASS with an inferior event-free survival (Figure 2e ; P ¼ 0.0025) and overall survival (Figure 2f ; P ¼ 0.0007) was confirmed in our TT3 trial that included 181 patients. Univariate analysis was applied to determine its predictive power in the context of other laboratory variables in the 351 TT2 patients. Patients with a high AASS level had high levels of C-reactive protein (P ¼ 0.003), creatinine (P ¼ 0.015) and lactate dehydrogenase (P ¼ 0.007), increased numbers of bone lesions on magnetic resonance imaging (P ¼ 0.009) and increased frequency of chromosomal abnormalities (hypodiploid, Po0.001), deletion of chromosome 13 (Po0.006) and amplification of chromosome 1q21 (Po0.001) (data not shown). Consistent with those findings, the high AASS group was predominantly the high-risk group defined by the 70-gene model (Figure 2g , Po0.001), 9 and the clinically more aggressive subgroups, PR (Proliferation) and MAF/MAFB (Figure 2h , Po0.001).
10 However, it did not exhibit an independent power in predicting patient outcome in a multivariate analysis of the TT2 sample. One possible reason is that AASS is highly correlated with the 70-gene model.
In this study, ALDH1 þ myeloma cells showed a significant increase in colony formation. GEPs performed on the ALDH1 þ MM cells revealed upregulation of genes related to the CIN pathway. These results suggest that ALDH1 þ MM cells are more proliferative than the ALDH1 -MM cells. We also demonstrated that transplantation of 10 000 ALDH1 þ ARP1 and KMS12BM MM Accepted article preview online 24 December 2013; advance online publication, 17 January 2014 cells, respectively, into NOD/SCID mice generated larger and more aggressive tumors relative to mice received ALDH1 À cells, demonstrating that ALDH1 þ MM cells have the potential of tumor-initiating cells. Thus, our data indicate that ALDH1-positive MM cells represent the fraction of the MMSC or represent a more differentiated proliferating progenitor population that has acquired stem cell features. Consistent with our discovery in MM, increased ALDH1 activity resulting in increased cell proliferation was reported in other cancers while downregulation of ALDH1 activity inhibited cancer growth. 11, 12 The majority of proliferating MM cells should be eliminated by chemotherapy; however, if proliferating progenitor cells hit by induction of oncogenes, loss of tumor suppressor genes or other gene mutations during progression, these proliferating cells acquire the capacity to self-renew indefinitely and transform into tumorinitiating cells. 13 Interestingly, NEK2, an important factor in the ALDH1/CIN signature mentioned above, was recently discovered by our group and also that high NEK2 induces CIN, drug resistance and cell proliferation. 7 It was intriguing to discover that NEK2, CDC2, TTK and AURKA were highly expressed and were under significant regulation in the embryonic stem (ES) cells, as these pluripotent 14 The high correlation of ALDH1 activity with CIN signatures suggests a mechanism that MM patients with increased ALDH1 activity are associated with a poor clinical outcome.
In summary, we have demonstrated that ALDH1 þ cells have the properties of MMSCs or MM-initiating cells, such as tumor initiation, drug resistance and cell proliferation. ALDH1 is a phenotypic marker for a functionally heterogeneous group of cells including CD34 þ hematopoietic stem cells, mesenchymal and endothelial cells in the bone marrow. 4 This makes it difficult to isolate MMSCs or progenitors by using ALDH1 alone. In future studies, we will purify MMSCs by combining ALDH1 with other criteria, such as Hoeschst efflux (SP) and myeloma-specific markers with kappa or lambda light chain, in primary MM samples.
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of clonal mature B cells in the blood, bone marrow and secondary lymphoid organs. Although peripheral CLL is quiescent, up to 1% of clonal cells are generated daily within proliferative centers.
1 CLL cells isolated from these structures display activation of survival and proliferation pathways (for example, phosphatidylinositol 3-Kinase (PI3K), Bruton's tyrosine kinase (BTK) and nuclear factor (NF-kB)) 1 because of interactions with accessory cells. In CLL, B-cell receptor (BCR) signaling represents one of the central pathways known to enhance survival and proliferation.
The importance of BCR signaling in CLL pathogenesis is underscored by the prognostic significance of somatic mutations in the immunoglobulin heavy-chain variable regions (IGHV) of the BCR. In general, CLL patients with unmutated IGHV have shorter progression-free survival and lower response rates.
2 CLL cells isolated from patients with unmutated IGHV rely heavily on survival signals and respond preferentially to BCR and Toll-like receptor 9 (TLR9) stimulation, 3 suggesting that therapies that block these signals may be particularly effective in this aggressive subset of CLL.
The recently unveiled mechanisms that control CLL cell survival and expansion have prompted the rapid development of therapeutics that disrupt CLL-microenvironment interactions and block BCR-driven activation (that is, fostamatinib, idelalisib and ibrutinib) [4] [5] [6] [7] and have demonstrated profound
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